Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2016-02-26 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2015
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the fourth quarter and full year 2015 for Sobi. It contains detailed financial statements, operational overviews, management commentary, and financial tables (e.g., income statements, key performance indicators). It is clearly a substantive financial report rather than a brief announcement or a certification, fitting the definition of an Interim/Quarterly Report. Q4 2015
2016-02-26 Swedish
Interim / Quarterly Report 2015
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report titled 'Q4 & FY REPORT 2015'. It contains detailed financial statements, business reviews, CEO statements, and financial summaries for both the fourth quarter and the full fiscal year. It is not an announcement of a report (RPA) nor a simple earnings release (ER), as it provides substantive financial data and analysis. It fits the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full fiscal year (Q4) and includes the full year performance. FY 2015
2016-02-26 English
Chief Medical Officer Birgitte Volck lämnar Sobi
Board/Management Information Classification · 98% confidence The document is a press release (PRESSMEDDELANDE) dated January 14, 2016, announcing that the Chief Medical Officer (CMO), Birgitte Volck, is leaving Sobi to join GlaxoSmithKline. This explicitly details a change in senior management/board personnel. According to the definitions, 'Board/Management Information' (Code: MANG) covers the 'Announcement of changes in the company's board of directors or senior management.' The document length is short (1987 chars), but its content is the announcement itself, not a notice about an attached report, making MANG the most appropriate classification.
2016-01-14 Swedish
Chief Medical Officer Birgitte Volck to leave Sobi
Board/Management Information Classification · 98% confidence The document is a short announcement detailing the departure of the Chief Medical Officer (CMO), Birgitte Volck, from Sobi and providing brief background information about Sobi and contact details. This type of announcement, concerning changes in senior management personnel, directly aligns with the definition for Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Given the content focuses entirely on a management change, MANG is the most appropriate classification.
2016-01-14 English
Lars Dreiøe blir Senior Vice President, Chief Quality & Compliance Officer på Sobi
Board/Management Information Classification · 98% confidence The document is a press release announcing a change in senior management: the appointment of Lars Dreiøe as Senior Vice President, Chief Quality & Compliance Officer. This directly aligns with the definition for Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2015-12-21 Swedish
Lars Dreiøe joins Sobi as Senior Vice President, Chief Quality & Compliance Officer
Board/Management Information Classification · 98% confidence The document is a press release announcing the appointment of a new Senior Vice President, Chief Quality & Compliance Officer (CQCO), Lars Dreiøe. This type of announcement concerns changes in the company's senior leadership team. Based on the provided definitions, this aligns directly with the 'Board/Management Information' category.
2015-12-21 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.